Transdermal Prescription Pain Products to Reach $9.2B by 2015

The incidence of several types of chronic and acute pain will increase significantly over the next few years, driving growth in transdermal pain products to reach $9.2 billion in 2015, according to a study by Greystone Research Associates.

Advertisement

According to George Perros, Greystone Research Managing Director, evolution in pain management guidelines and a better appreciation for pain-associated morbidity by clinicians are making pain management more essential for patients. Greystone’s study, “Transdermal Pain Management to 2015,” analyses commercial transdermal prescription drug products and development-stage candidates, as well as examining key factors influencing market demand and shaping growth prospects.

Read the Greystone Research Associates press release on transdermal pain products.

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

  • As the ASC industry continues to grow alongside new waves of surgical innovation, patient preferences and shifts to value-based care,…

  • A Pleasant View, Utah-based physician has been indicted on charges of obtaining unapproved drugs from China and selling them to…

  • From payer obstacles to operational pressures, five ASC leaders discuss the biggest frictions they’re facing. Note: Responses were lightly edited.…

Advertisement

Comments are closed.